BMEA: Advancing Menin and oral GLP-1 therapies for diabetes, with phase II trials and strong financial runway

The company is advancing Menin-targeted and oral GLP-1 therapies for diabetes and obesity, with phase II trials focusing on key patient subgroups and a phase I oral GLP-1 study targeting better tolerability. Financial runway extends into 2027, with partnering under consideration.

Based on Biomea Fusion, Inc. [BMEA] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 3 2025